David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006.
UCART22: anti-tumor activity observed in 60% of patients at DL3 using FCA lymphodepletionUCART123: 25% of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a. | December 13, 2022